The maximal dosage should not exceed 100 mg/day.Patients treated with pituitary irradiation should be withdrawn from Parlodel therapy on a yearly basis to assess both the clinical effects of radiation on the disease process as well as the effects of Parlodel therapy. The elimination of parent drug from plasma occurs biphasically, with a terminal half-life of about 15 hours.

Bromocriptine is also used together with proper diet and exercise to lower blood sugar levels in patients with type 2 diabetes.

Patients with a history of evidence of peptic ulceration should be closely monitored when receiving the treatment.Since, especially during the first few days of treatment, hypotensive reactions may occasionally occur and result in reduced alertness, particular care should be exercised when driving a vehicle or operating machinery.Among patients on BROMOCRIPTINE, particularly on long-term and high-dose treatment, pleural and pericardial effusions, as well as pleural and pulmonary fibrosis and constrictive pericarditis have occasionally been reported. In addition, BROMOCRIPTINE does not impair the puerperal involution of the uterus and does not increase the risk of thromboembolism.BROMOCRIPTINE has been shown to arrest the growth or to reduce the size of prolactin-secreting pituitary adenomas (prolactinomas).In acromegalic patients - apart from lowering the plasma levels of growth hormone and prolactin - BROMOCRIPTINE has a beneficial effect on clinical symptoms and on glucose tolerance.BROMOCRIPTINE improves the clinical symptoms of the polycystic ovary syndrome by restoring a normal pattern of LH secretion.Because of its dopaminergic activity, BROMOCRIPTINE, in doses usually higher than those for endocrinological indications, is effective in the treatment of Parkinson's Disease, which is characterised by a specific nigrostriatal dopamine deficiency. It shows a high affinity for CYP3A and hydroxylations at the proline ring of the cyclopeptide moiety constitute a main metabolic pathway. BROMOCRIPTINE can be given either alone or - at early as well as advanced stages - combined with other anti-Parkinsonian drugs. However, given the low therapeutic concentrations of free bromocriptine in patients, a significant alteration of the metabolism of a second drug whose clearance is mediated by CYP3A4 should not be expected. Women of childbearing age who do not wish to conceive should therefore be advised to practice a reliable method of contraception.Hypotensive reactions may be disturbing in some patients during the first few days of treatment and particular care should be exercised when driving vehicles or operating machinery.Patients being treated with bromocriptine and presenting with somnolence and/or sudden sleep episodes must be advised not to drive or engage in activities where impaired alertness may put themselves or others at risk of serious injury or death (eg. Prolactin affects the menstrual cycle and milk production. Severe interactions of bromocriptine include: almotriptan; ... Pregnancy and Lactation. Usually a 4-8 week withdrawal period is adequate for this purpose. Prolactin-secreting adenomas may expand during pregnancy. Bromocriptine has been used to treat prolactinomas and gigantism (acromegaly) indications in patients aged 7 or above and case series have been documented in the literature.

In women using Bromocriptine for postpartum suppression of lactation (breast feeding), there have been a small number of reported cases of serious complications including strokes and seizures. Peak plasma levels are reached within 1-3 hours. Bromocriptine should only be used orally in strengths up to 2.5 mg to inhibit lactation when medically indicated, such as in case of intrapartum loss, neonatal death or HIV infection of the mother.

Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.